UK markets closed
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • FTSE 250

    23,658.94
    +26.10 (+0.11%)
     
  • AIM

    1,275.74
    +3.60 (+0.28%)
     
  • GBP/EUR

    1.1711
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • BTC-GBP

    34,675.89
    -746.62 (-2.11%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • DOW

    34,584.88
    -166.44 (-0.48%)
     
  • CRUDE OIL

    71.96
    -0.65 (-0.90%)
     
  • GOLD FUTURES

    1,753.90
    -2.80 (-0.16%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • HANG SENG

    24,920.76
    +252.91 (+1.03%)
     
  • DAX

    15,490.17
    -161.58 (-1.03%)
     
  • CAC 40

    6,570.19
    -52.40 (-0.79%)
     

VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Biopharma veteran enhances VectivBio’s legal, regulatory and operational capabilities

BASEL, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Scott Applebaum as Chief Legal Officer & Corporate Secretary. Mr. Applebaum brings over two decades of legal, regulatory and operational experience in the biopharmaceutical industry to VectivBio.

“Scott has a great understanding of the legal and regulatory intricacies of the biotech and rare disease space,” said Luca Santarelli, M.D., Founder and CEO of VectivBio. “His knowledge and leadership will help guide us as we advance our Phase 3 trial of apraglutide in Short Bowel Syndrome with Intestinal Failure, pursue potential approval and expand our pipeline. Scott shares our passion for helping patients suffering from severe rare diseases and we are thrilled to have him join VectivBio.”

Scott Applebaum stated, “The VectivBio team is committed to developing innovative treatments to transform patients’ lives. I am excited to return to the field of rare diseases and to join this top-notch team on this mission and look forward to helping the company achieve its goal of delivering medicines to those in need.”

Prior to joining VectivBio, Mr. Applebaum was the Chief Legal & Compliance Officer and Senior Vice President of Regulatory Affairs at Trevena, where he played a key role in gaining FDA approval for their lead product, Olinvyk®. Previously, he served as President of Context Therapeutics and was General Counsel at Vitae Pharmaceuticals, where he was instrumental in their sale to Allergan. Formerly, he was Chief Legal Officer for Medgenics, a rare genetic disease company. Mr. Applebaum spent 10 years at Shire, where his roles included heading up their global legal group, managing their neuroscience portfolio outside of the United States as SVP of the Neuroscience Business Unit and leading the implementation and execution of the regulatory strategy for all of Shire’s specialty pharmaceutical products worldwide as SVP of Global Regulatory Affairs, Quality Assurance and Compliance. Previously, he was Senior Counsel for medicines and medical imaging at Bristol Myers Squibb.

Prior to his career in the biopharmaceutical industry, Mr. Applebaum was a lawyer at Dechert LLP. He received his J.D. from Stanford Law School and a B.S. in Economics, Finance and Accounting from the University of Pennsylvania.

About VectivBio AG

VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. VectivBio is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal diseases. Apraglutide is currently being evaluated in a global Phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure. VectivBio also plans to initiate clinical studies of apraglutide in additional indications, including graft versus host disease, where GLP-2 is believed to be central to disease pathophysiology.

Forward Looking Statements

Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic and those risks and uncertainties identified in the “Risk Factors” section of VectivBio’s Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on April 8, 2021 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

For more information visit www.vectivbio.com, and follow us on LinkedIn and Twitter.

Investors
Graham Morrell
graham.morrell@vectivbio.com

Media
Morgan Warners
+1 (202) 295 0124
morgan.warners@fgh.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting